GW Pharmaceuticals tests epilepsy drug in man as FDA softens stance

A.B. | ShareCast | 18 Sep, 2013 11:09 - Updated: 11:59 | | |


Cannabis-derived drug developer GW Pharmaceuticals has begun human trials of its epilepsy treatment.

The AIM- and Nasdaq-listed company said the novel drug candidate, currently named GWP42006, was one of its most promising and looked to have significantly fewer side effects than currently approved anti-epileptic drugs.

Dr. Stephen Wright, Director of Research and Development at the company said advancing GWP42006 to a first dose in man was a significant milestone in the development of this candidate.

“The decision to progress into Phase 1 follows several years of highly promising pre-clinical research," he added.

"We believe that GWP42006 has the potential to become an important advance in the treatment of epilepsy, a condition for which there remains a substantial unmet medical need."

Research with the Reading School of Pharmacy in Buckinghamshire has shown that GWP42006 not only exerts significant ability to treat seizures in a wide range of preclinical models of seizure and epilepsy, but is also better tolerated by patients compared to existing anti-epileptic drugs.

The company has been encouraged by recent interest in its products in the US. That arose after the pharmaceutical regulator, the Food and Drug Administration [FDA], allowed US epilepsy specialists and patient organizations to carry out treatment on a small number of pediatric epilepsy patients with a cannabidiol [CBD] formulation supplied by GW. These activities may generate initial evidence to add CBD as a further pipeline candidate for clinical evaluation in epilepsy.

Recent third quarter showed net cash of $66.3m thanks to a US IPO in May that raised $30.4m.

Shares in GWP were up 1.4% to 72p at 11:12 on Wednesday.


More news

16:36 FTSE 250 Movers: Transport surges, energy sector dips

Stagecoach saw shares surge after its 90%-owned joint venture with Virgin Rail won the contract from the Department for Transport to run the new InterCity East Coast franchise for eight years from March 2015.

16:25 Market overview: Brent drops after OPEC keeps target unchanged

1625: Brent futures are down over 6% at $73.02 a barrel after OPEC held its production target, while WTI crude has fallen 5.7% to $69.46/bbl, its first time below $70 since June 2010.

16:13 FTSE 100 movers: Supermarkets fall amid Campylobacter outrage, energy stocks drop

The share price of UK supermarket chain Sainsbury was under pressure on Thursday after Shore Capital downgraded its rating from 'hold' to 'sell', saying investors should expect a "material contraction in profitability". The broker said it sees "few attractions in holding Sainsbury's shares". It expects a 30% "reset" in earnings per share and is forecasting three years of declines in Sainsbury's profits and dividends.

15:36 Charles Stanley swings to £3.9m first-half loss

Investment management firm Charles Stanley has reported a £3.9m loss for the six months to 30 September following increased costs during a period of static markets.

15:23 Smith & Nephew's chief executive Bohuon slams reports of Sanofi appointment

Smith & Nephew’s shares rose after chief executive Olivier Bohuon reportedly told employees he has no intention of leaving the company following speculation that he was taking the helm of Sanofi.

15:21 Mulberry poaches Celine's design director Johnny Coca

Mulberry appointed Johnny Coca as its new creative director more than a year after the departure of Emma Hill.

15:18 Front month Brent crude futures are down 3.5% to $75.05 per barrel

15:13 Ryanair to replace flight manuals with iPads

After allowing passengers to carry an extra cabin bag on their planes, Ryanair has decided to save space by binning flight manuals.

15:44 Ali al-Naimi says OPEC will not cut production

The Organisation of Petroleum Exporting Countries (OPEC) decided on Thursday to maintain its current “official” output target unchanged, at 30m barrels per day, surprising analysts which had expected at least some token action to be decided upon to slow the slide in crude prices.

14:53 OPEC maintains official output target at 30m - Unconfirmed



Mario Draghi, President of the European Central Bank, ECB
Draghi says ECB unanimously supports additional measures

The ECB governing council stands unanimously in favour of using further ?unconventional instruments?.


Support and resistance levels Support and resistance levels 27th november 2014